new glp 1 agonist novo nordisk Nordisk's weight-loss pill wins FDA approval Novo Nordisk: A New Boost
Description
In general, DPP-4 inhibitors are effective at promoting moderate lowering of A1C and are associated with few adverse events
2 In the full study population, breast cancer was diagnosed in 1.62% (247/15,264) of women with GLP-1 exposure compared with 2.47% (2,381/96,382) of women without exposure, corresponding to an odds ratio (OR) of 0.649 (95% CI, 0.5690.741
Meier 2012)
The net result is maintained or improved glucose homeostasis, while the energy expenditure and lipolytic benefits of glucagon receptor activation are preserved [3]
Integration of GLP-1RAs with Guideline-directed Medical Therapy and the Management of Other Comorbidities A key practical question is how to integrate GLP-1RAs with existing therapies for HFpEF and its common comorbidities
